February 28, 2022: Safety Bulletin - Mitigating Risk for Medication Errors Involving Paxlovid
Paxlovid (a co-packaged product containing nirmatrelvir and ritonavir tablets) was recently approved by Health Canada for the treatment of mild to moderate COVID-19 in adults at high risk for progression to severe disease. Several key safety considerations have been identified: (1) the need for product manipulation before it is dispensed for use by patients with moderate renal dysfunction, (2) the display of critical information (e.g., dosing) about the co-packaged product in prescribing and other medication software, and (3) the need for updated drug interaction checking software. Read more ...
